Female Sexual Dysfunction - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Female Sexual Dysfunction - Pipeline Review, H1 2016

Female Sexual Dysfunction - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Female Sexual Dysfunction - Pipeline Review, H1 2016
Published Jun 15, 2016
81 pages — Published Jun 15, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Female Sexual Dysfunction - Pipeline Review, H1 2016, provides an overview of the Female Sexual Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction
- The report reviews pipeline therapeutics for Female Sexual Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Female Sexual Dysfunction therapeutics and enlists all their major and minor projects
- The report assesses Female Sexual Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Female Sexual Dysfunction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline proje

  
Source:
Document ID
GMDHC8200IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Female Sexual Dysfunction Overview81
Therapeutics Development92
  Pipeline Products for Female Sexual Dysfunction Overview91
  Pipeline Products for Female Sexual Dysfunction Comparative Analysis101
Female Sexual Dysfunction Therapeutics under Development by Companies111
Female Sexual Dysfunction Therapeutics under Investigation by Universities/Institutes121
Female Sexual Dysfunction Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Female Sexual Dysfunction Products under Development by Companies161
Female Sexual Dysfunction Products under Investigation by Universities/Institutes171
Female Sexual Dysfunction Companies Involved in Therapeutics Development188
  Apricus Biosciences, Inc.181
  Emotional Brain BV191
  EndoCeutics, Inc.201
  M et P Pharma AG211
  Palatin Technologies, Inc.221
  Re-Pharm Limited231
  TherapeuticsMD, Inc.241
  Valeant Pharmaceuticals International, Inc.251
Female Sexual Dysfunction Therapeutics Assessment2610
  Assessment by Monotherapy Products261
  Assessment by Combination Products271
  Assessment by Target282
  Assessment by Mechanism of Action302
  Assessment by Route of Administration322
  Assessment by Molecule Type342
Drug Profiles3631
  (sildenafil citrate + testosterone) Drug Profile362
  alprostadil Drug Profile387
  bremelanotide Drug Profile455
  prasterone Drug Profile502
  S1B-3006 Drug Profile521
  S1B-307 Drug Profile531
  SIP-104 Drug Profile542
  Small Molecule for Sexual Dysfunction Drug Profile561
  Small Molecules to Agonize Dopamine for Sexual Dysfunction Drug Profile571
  SPT-201 Drug Profile581
  Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction Drug Profile591
  TBS-2 Drug Profile604
  TX-004HR Drug Profile643
Female Sexual Dysfunction Dormant Projects673
Female Sexual Dysfunction Discontinued Products701
Female Sexual Dysfunction Product Development Milestones719
  Featured News &Press Releases711
    May 14, 2016: TherapeuticsMD Presents Poster at ACOG 2016 with Additional Secondary Endpoint Data from Phase 3 Rejoice Trial711
    Mar 02, 2016: TherapeuticsMD to Present Data from Phase 3 Rejoice Trial at Upcoming Investor &Medical Conferences711
    Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting721
    Feb 18, 2016: TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women s Sexual Health Annual Meeting721
    Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction731
    Jan 05, 2016: DHEA Improves Vaginal Discomfort After Menopause731
    Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction741
    Dec 07, 2015: TherapeuticsMD Announces Positive Top-Line Results from its Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy Treated with 25 mcg, 10 mcg or 4 mcg of TX-004HR751
    Nov 02, 2015: Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference761
    Sep 09, 2015: TherapeuticsMD Announces Presentations at The North American Menopause Society 2015 Annual Meeting761
    Aug 20, 2015: S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder761
    Aug 19, 2015: Apricus Biosciences Announces it is Seeking a Global Partner for Femprox, a Novel Treatment for Female Sexual Dysfunction771
    Aug 18, 2015: Palatin Technologies Supports FDA's Approval of the First-Ever Treatment for Female Sexual Dysfunction781
    Jun 11, 2015: Trimel Confirms Next FDA Meeting on TEFINA791
    Jun 09, 2015: TherapeuticsMD Completes Enrollment in The Rejoice Trial, a Phase 3 Clinical Trial of TX-004HR791
Appendix802
  Methodology801
  Coverage801
  Secondary Research801
  Primary Research801
  Expert Panel Validation801
  Contact Us801
  Disclaimer811

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Female Sexual Dysfunction - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Female-Sexual-Dysfunction-Pipeline-Review-H1-2016-2088-15954>
  
APA:
Global Markets Direct - Market Research. (2016). Female Sexual Dysfunction - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Female-Sexual-Dysfunction-Pipeline-Review-H1-2016-2088-15954>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.